Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.76 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 12/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104641 | 0.90 | ILK (0.80) | ILKRXRARXRBRXRGCA1 | |
| SCHEMBL9103873 | 0.90 | ILK (0.80) | ILKRXRARXRBRXRGCA1 | |
| SCHEMBL8536228 | 0.86 | ILK (1.00) | ILKRXRARXRBRXRGMAPKAPK2 | |
| SCHEMBL8533755 | 0.81 | ILK (0.68) | ILKCA1CA2CA9MALT1 | |
| SCHEMBL8612124 | 0.78 | ILK (0.84) | ILKRXRARXRBRXRGMAPKAPK2 | |
| SCHEMBL17085100 | 0.75 | ILK (0.59) | ILKRXRARXRBRXRGCA1 | |
| SCHEMBL17087637 | 0.73 | ILK (0.74) | ILKRXRARXRBRXRG | |
| SCHEMBL17077247 | 0.73 | ILK (0.75) | ILKRXRARXRBRXRG | |
| SCHEMBL17085060 | 0.72 | ILK (0.55) | ILKRXRARXRBRXRGCA1 | |
| SCHEMBL17085049 | 0.71 | ILK (0.55) | ILKRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2642856-B1 | INTEGRIN-LINKED KINASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8658647-B2 | Integrin-linked kinase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | PTK2, ITGB1, ITGB2 | ILK 8/4885RXRA 3080/4885RXRB 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.